200120172020

The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor

Natasha Cowan | 13 July 2021

Hero image

Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals how life science companies can cut through the noise to drive uptake of innovative therapies, including novel TYK2 inhibitors.

During the last two decades, the landscape for psoriasis treatment has exploded. The advent of biologic therapies at the turn of the millennium and the subsequent development of T-cell targeted therapies and tumor necrosis factor (TNF) inhibitors have given patients therapeutic options beyond traditional treatments such as topical steroids, tar preparations, oral systemics, and light therapy. Suddenly, those with more severe  psoriasis had safer and more effective treatment options that delivered the life-changing potential for clear skin.

Today, some of the most innovative therapies in development are Janus kinase (JAK) inhibitors, and the latest ‘game changer’ Tyrosine kinase 2 (TYK2) inhibitors.

The healthcare press has described TYK2 inhibitors as having the potential to revolutionize psoriasis treatment. The inhibitors work by  blocking the action of TYK2 and preventing the downstream signaling effects of cytokines IL-12, IL-23, and type I interferons, thereby clinically improving psoriatic plaques.

In contrast to many existing treatments for more difficult-to-control forms of psoriasis which are intravenous, TYK2 inhibitors– like Bristol Myers Squibb’s deucravacitinib (BMS-986165) –are being trialed as oral medications, which could vastly improve the patient experience.The results of the deucravacitinib Phase 3 studies caused a stir across the industry. A significant number of patients achieved a Psoriasis Area and Severity Index (PASI) 75 response, which means the patients score on the index dropped by 75%, and a static Physician’s Global Assessment Score of clear or almost clear (sPGA 0/1).

In a disease where the impact on patients’ quality of life has been likened to other chronic illnesses, like diabetes and coronary heart disease, the impact of these novel treatments could be ground-breaking. However, despite the increasing number of treatments available, a survey by the U.S National Psoriasis Foundation found 52% of patients with psoriasis are dissatisfied with treatment. In addition, recent data show moderate and severe psoriasis are often undertreated with more than 50% of patients prescribed only topical therapies.

So, if striving for clear or almost clear skin is a realistic treatment goal, why are healthcare professionals refraining from prescribing more efficacious treatments, and what does this mean for yet-to-be approved TYK2 inhibitors?

Download the full  article to:

  • Explore the treatment  landscape
  • Learn about the barriers keeping healthcare professionals from prescribing treatments beyond topicals
  • Find out about strategies for driving  uptake of novel psoriasis therapies.

Download the PDF

Latest articles

News

Fishawack Health Announces New CEO Jonathan Koch

16 September 2021

Thought Leadership

10 tips for a faster life science launch

14 September 2021

News

Paving the way for the next generation of healthcare communicators

01 September 2021

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.